Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing by Goubert, Désirée et al.
  
 University of Groningen
Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of
Epigenetic Editing





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Goubert, D., Koncz, M., Kiss, A., & Rots, M. G. (2018). Establishment of Cell Lines Stably Expressing
dCas9-Fusions to Address Kinetics of Epigenetic Editing. In Epigenome Editing: Methods and Protocols
(Vol. 1767, pp. 395-415). Humana Press.  Methods in Molecular Biology https://doi.org/10.1007/978-1-
4939-7774-1_22
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Establishment of cell lines stably expressing dCas-fusions to address kinetics of epigenetic editing 
Désirée Goubert1, Mihály Koncz2,3, Antal Kiss2 and Marianne G Rots1,* 
1Epigenetic Editing, Department of Pathology and Medical Biology, University of Groningen, 
Hanzeplein 1, 9713 GZ Groningen, the Netherlands. 
2Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, 
Temesvári krt. 62, 6726 Szeged, Hungary 
3Doctoral School in Biology, Faculty of Science and Informatics, University of Szeged, Szeged, 
Hungary 
*Corresponding author: m.g.rots@umcg.nl 
 
Running Header – kinetics of epigenetic editing 
 
Abstract  
Epigenetic editing is a promising approach to modulate the local chromatin environment of 
target genes with the ultimate goal of stable gene expression reprogramming. Epigenetic 
editing tools minimally consist of a DNA binding domain and an effector domain. The 
CRISPR-dCas9 platform, where mutations in the nuclease domains render the Cas9 protein 
inactive, is widely used to guide epigenetic effectors to their intended genomic loci. Its flexible 
nature, simple use and relatively low cost have revolutionised the research field of epigenetic 
editing. Although effective expression modulation is readily achieved, only a few studies have 
addressed the maintenance of the induced effects on endogenous loci. Here, we describe a 
detailed protocol to engineer cells that stably express the CRISPR-dCas9-effectors. The 
protocol involves modification of published dCas9-based plasmid vectors for easy transfer of 
the effector domain between the vector designed for transient transfection and the vector used 
for establishing cell lines stably expressing the dCas9-effector fusion protein. Transient 
transfection of the dCas9-effector producing cells with sgRNA expressing plasmids allows 
studying of the maintenance of epigenetic editing. Targeting various genes in different 
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chromatin contexts and/or co-targeting multiple CRISPR-dCas9-effectors can be used to 
unravel rules underlying maintained gene expression reprogramming.  
 
Key Words: CRISPR-dCas9; fusion proteins, epigenetic reprogramming; epigenetic memory 
 
1 Introduction 
Epigenetic editing has the potential to treat or even cure diseases by stably reprogramming the 
chromatin environment and achieving maintained gene activation or gene silencing. To this 
end, a one-and-done approach is envisioned, where patients would receive treatments with 
epigenetic editing tools, after which the rewritten epigenetic environment is stably maintained. 
In general, DNA methylation and histone modifications are faithfully copied during cell 
divisions to assure maintenance of the cell phenotype [1-3]. Therefore, deliberately editing 
epigenetic marks bears the promise to make permanent changes [4-7]. However, conflicting 
data exist with regard to the maintenance of the newly established epigenetic states. For 
example, gene repression by DNA methylation has been shown to be maintained for the SOX2 
gene [6], while DNA methylation-induced repression was not maintained for the VEGF-A gene 
[8]. In this respect, Amabile et al. showed that for most loci efficient long-term memory of an 
induced repressive epigenetic state was only obtained after targeting a combination of 
repressors (KRAB-DNMT3A-DNMTL) [9]. 
Although various DNA binding platforms have been explored previously to target endogenous 
genes [10], none of them is as suitable as the CRISPR-dCas9 platform is for large scale 
multiplex investigations of the maintenance of epigenetic marks on gene expression [11]. An 
experimental system employing transient expression of sgRNAs in engineered cell lines stably 
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expressing dCas9-effector fusions thus would provide a flexible model to address the influence 
of native chromatin states on long-term kinetics of epigenetic editing. We previously used such 
a model to investigate the sustainability of SPDEF gene repression in MCF-7 cell lines stably 
expressing dCas9 fused either with the non-catalytic transcriptional repressor SKD, or with 
epigenetic editors and their mutants, G9a and SUV39h1 (for H3K9me), the SET domain of 
EZH2 (for H3K27me), or a chimeric DNMT3A-3L fusion (for DNA methylation). The 
sgRNAs targeting the SPDEF promoter region were introduced by transient transfection. 
Repression of gene expression was observed in cells expressing dCas9-SKD, -SUV39H1, -
EZH2 and -DNMT3A-3L, but this repression was not maintained when measured after 14 days. 
Interestingly, the repression of SPDEF was sustained in cells expressing dCas9-G9a, while 
short-term expression of the sgRNAs in the dCas9-G9A mutant cells regained activation after 
14 days [7]. 
Conceptually, sustained gene re-expression is more challenging to achieve than sustained 
silencing. Nevertheless, by inducing the endogenous expression of Brn2, Ascl1, and Myt1l 
genes, Black et al. were able to stably convert fibroblasts into neuronal cells. To this end, 
primary mouse embryonic fibroblasts were engineered to constitutively express VP64-dCas9-
VP64, and sgRNAs were delivered through transient transfection to investigate the 
maintenance of the induced effects on the three neurogenic genes. Upon transiently targeting 
of VP64, sustained activation of the target genes was demonstrated at day 18, which was 
associated with effective reprogramming of these embryonic cells [12]. Although constitutive 
lentiviral expression induced neuronal reprogramming more effectively, these, and similar data 
for e.g. MyoD1 [13, 14], indicate promise for transient, non-integrative molecular tools in 
stable cell reprogramming.  
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Despite these promising transdifferentiation data, we and others demonstrated that the 
induction of gene expression by non-catalytic VP64-fusions generally is transient in adult cells 
[15, 16]. The direct rewriting of chromatin signature states might be more effective in inducing 
sustained gene re-expression. Using doxycycline-inducible stable cells lines, we previously 
demonstrated for a hypermethylated gene, that although induction of local methylation of 
H3K4 is sufficient to directly initiate gene expression, no sustained gene re-expression could 
be observed [4]. Interestingly, the induced reactivation was sustained for a 
hypomethylated gene and even reinforced ten days after transfection [4].  
To further identify factors that determine maintenance of epigenetic profiles, studies focusing 
on long-term kinetics of induced epigenetic changes are needed. Towards this end, stable cell 
lines can be engineered to continuously expressing dCas9-effectors, which can be transiently 
transfected with sgRNAs temporarily targeting the effectors to the genes of interest [7]. 
Although these cell lines constantly express either the transcriptional repressor (SKD), 
activator (VP64), or epigenetic editors, the sgRNAs can only for short time periods guide the 
effectors to the gene of interest (one-and-done approach). As controls, stable cell lines 
expressing mutant forms of the epigenetic editors will determine whether the observed effects 
can be attributed to the catalytic activity of the enzymes, or to for example steric hindrance or 
recruitment of other chromatin remodelers. Similarly, a stable cell line expressing dCas9 
without an effector will control for the effects of dCas9 binding. Here, we provide detailed 
protocols to construct transient expression plasmids and stable dCas9 expressing cell lines and 
describe the procedure to transiently transfect these stable cells with sgRNA plasmids to 






2.1 Molecular biology reagents and equipment 
1. Nuclease-free water 
2. Plasmid DNA extraction kit  
3. Restriction enzymes: AscI, AgeI, PacI, BsmBI,  PacI, BamHI, NotI, MluI, 
AsiSI. For faster digestion the use of FastDigest preparations of Thermo 
Scientific or Timer-Saver qualified preparations of New England Biolabs is 
recommended.   
4. T4 DNA ligase (400U/µl) and ligase buffer 
5. High fidelity DNA polymerase (Phusion DNA polymerase) and buffer 
6. dNTPs (10mM) 
7. Oligonucleotides  
A. Sequencing primer 1: TACAAGGATGACGATGACAAG (pMLM3705 
positions 4591 – 4612) 
B. Sequencing primer 2: TAGAAGGCACAGTCGAGG  (pMLM3705 
positions 4840 – 4857, complementary strand, BGH Reverse, 
https://www.addgene.org/mol-bio-reference/sequencing-primers/) 
C. Sequencing primer 3: CAGGGTTATTGTCTCATGAGCGG (MLM3636  
positions 2183 – 2205, OS280 primer, https://www.addgene.org/43860/) 
D. Sequencing primer 4: CAGCGGGGCTGCTAAAGCGCATGC (pHAGE 
EF1α dCas9-VP64 positions 161-184, complementary strand, MSCV-rev 
primer)  
E. Oligo 1: CGCGCCCATATGTTAATTAACAATTAA (complementary to 
Oligo 2, the duplex has AscI- and AgeI-compatible single-stranded ends)  
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F. Oligo 2: CCGGTTAATTGTTAATTAACATATGGG (complementary to 
Oligo 1, the duplex has AscI- and AgeI-compatible single-stranded ends) 
G. Oligo 3:  GATCCACACGCGTTAAGCGATCGCGC (complementary to 
Oligo 4, the duplex has BamHI- and NotI-compatible single-stranded 
ends) 
H. Oligo 4: GGCCGCGCGATCGCTTAACGCGTGTG (complementary to 
Oligo 3, the duplex has BamHI- and NotI-compatible single-stranded 
ends) 
I. Primers for PCR amplification of effector domains: see below at the 
specific steps 
8. Equipment for gel electrophoresis of DNA fragments 
9. A thermocycler for PCR-amplification of DNA fragments 
10. Agarose and Tris-borate-EDTA buffer (50 mM Tris base, 50 mM boric acid, 1 
mM EDTA, pH8.3) for agarose gel electrophoresis  
11. Ethidium bromide or other fluorescent dye for visualizing DNA fragments 
12. DNA fragment size marker (e.g. 1 Kb Plus DNA Ladder)  
13. Razor blades and gel extraction kit  
14. E. coli (e.g. DH10B, DH5α) cloning host (chemically competent) 
15. LB growth medium for bacteria 
16. 100 mg/ml ampicillin stock solution in water, filter-sterilized 
17. LB agar plates 
18. 1 M Tris-HCl, pH7.5 
19. 1 M NaCl 
20. TE buffer: 10 mM Tis-HCl, pH 7.5 




1. pMLM3705 (A gift from Keith Joung, Addgene plasmid  #47754) 
2. MLM3636 (A gift from Keith Joung, Addgene plasmid #43860) 
3. pHAGE EF1α dCas9-VP64 (A gift from Rene Maehr and Scot Wolfe, Addgene 
plasmid #50918) 
4. psPAX2 (Lentiviral packaging plasmid; a gift from Didier Trono, Addgene 
plasmid #12260) 
5. pMD2.G VSV-G (Envelope expressing plasmid; a gift from Didier Trono, 
Addgene plasmid #12259) 
 
2.3 Cell culture and transfection (see Notes 1 and 2) 
1. HEK293T cells (ATCC: CRL-3216) + Medium (DMEM + 10% FBS + 1% L-
glutamine + 1% gentamicin) 
2. Cell culture flasks and plates 
3. Cell culture reagents (including Phosphate Buffered Saline, trypsin) 
4. Incubator set to 37°C and 5% CO2, humidified atmosphere 
5. Transfection medium (f.e. Lipofectamine (LTX*PLUS), Plus reagent) 
6. Host cells for transfection/transduction and suitable growth medium 
7. 10 cm plates (tissue culture treated) 
8. Polybrene (Hexadimethrine bromide) 
9. Puromycin (1µg/ml) 
10. 10 ml syringes 
11. 0.45 μ Surfactant-Free Cellulose Acetate (SCFA) filter 
12. 15 ml tubes 
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13.  Disinfectant (f.e. 1% sodium hypochlorite) and an appropriate waste container 
(f.e. vacuum bag) 
 
3 Methods 
3.1 Construction of plasmids for transient expression of dCas9-effectors  
To validate the effector function of dCas9-effector fusions before constructing the stable cell 
lines, the dCas9-effector and the sgRNA(s) can be tested in a transient expression system. To 
facilitate construction of fusions between dCas9 and different effectors, the plasmid 
pMLM3705 encoding a dCas9-VP64 fusion (Figure 1) is converted into a general acceptor 
plasmid by deleting the 159 bp AscI-AgeI fragment carrying the VP64 gene and replacing it 
with the double-stranded oligonucleotide Oligo 1 + Oligo 2 (see 2.1 step 7 E & F) containing 
a PacI site. Ligation of the Oligo 1 + Oligo 2 duplex to the pMLM3705 backbone restores the 
AscI site. The new plasmid called pdCas9-NED (No Effector Domain) will encode the fusion 
protein dCas9-SV40 nuclear localization signal (NLS) - 3xFLAG peptide, and will serve as an 
acceptor for genes of effector domains (Figure 1). PCR-amplified fragments coding for an 
effector can be cloned between the AscI and the PacI sites of pdCas9-NED (Figure 1). 
 
3.1.1 Construction of the vector plasmid pdCas9-NED 
1. Digestion of pMLM3705. Prepare the reaction mixture: 
• 2 to 4 µg pMLM3705 plasmid DNA 
• 10 µl 10X FastDigest Green Buffer 
• 2 µl FastDigest AscI 
• 2 µl FastDigest AgeI 
• H2O to 100 µl final volume 
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Incubate for 1 hour at 37 °C, then check completeness of digestion by running 
10 μl of the digestion mixture in a 1% agarose gel alongside with undigested 
control. 
2. Annealing of Oligo 1 and Oligo 2. The duplex will contain a PacI site and carry 
AscI- and AgeI-compatible single-stranded ends. 
Dissolve the oligonucleotides to 100 µM in TE buffer. Combine:  
• 5μl Oligo 1 
• 5 µl Oligo 2  
• 1 µl 1 M Tris-HCl pH7.5 
• 2 µl 1 M NaCl 
• 7 µl H2O  
Place the tube to 95 °C (a water bath or a thermocycler) for 5 minutes, then let it 
slowly cool down to room temperature. The annealed duplex can be stored in ice or 
at -20 °C. 
3. If the digestion of pMLM3705 is complete (see 3.1.1. step 1), load the rest of the 
digestion mixture on a preparative 0.8% agarose gel, and isolate the large fragment 
(7626 kb) by using a gel extraction kit. Determine the concentration of the purified 
fragment by measuring A260 (Nanodrop). 
4. Ligation of the annealed oligonucleotides to the purified vector fragment. Prepare 
the following reaction mixture:  
• ~200 ng linear vector DNA 
• Annealed Oligos 1+2 (2 to 10-fold molar excess over the vector) 
• 2 µl 10x T4 DNA ligase buffer  
• 1 µl T4 DNA ligase 
• H2O to 20 µl final volume  
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Mix gently and incubate for 30 minutes - 2 hours at room temperature (see Notes 3 and 
4).  
5. Transformation of E. coli with the ligated DNA: 
• Add 2 µl ligation mixture to 100 µl competent E. coli cells  
• Mix gently 
• Place the tubes on ice for 30 minutes 
• Place the tubes to 42 °C for 2 minutes 
• After the heat-shock, pipette the mixture into a 15 ml sterile tube containing 500 
µl LB medium. 
• Incubate for an hour in a rotating incubator at 37 °C 
• Spread 100 µl cell suspension on LB agar plates containing 100 µg/ml 
ampicillin, and incubate at 37 °C overnight. 
6. Analysis of the clones:  
• Seed 3 ml of LB-ampicillin medium in 15 ml sterile tubes with single colonies 
and incubate the cultures overnight at 37 °C  
• Isolate plasmid DNA using a miniprep plasmid DNA isolation kit 
• Analyze the structure of the plasmids by restriction digestion. The sought-after 
plasmid (pdCas9-NED) should contain a PacI site. For example, a PacI + EcoRV 
double digestion of pdCas9-NED should produce 5251 and 2402 bp fragments. 
Select 2 – 3 plasmids with correct-looking restriction pattern, and verify the 
presence of the inserted oligonucleotide by sequencing across the AscI and PacI 






3.1.2 Construction of dCas9-effector fusions 
1. Digestion of pdCas9-NED with AscI and PacI. Prepare the following reaction 
mixture: 
• 2 to 4 µg pdCas9-NED plasmid DNA  
• 10 µl 10X FastDigest Green Buffer 
• 2 µl FastDigest AscI  
• 2 µl FastDigest PacI 
• H2O to 100 µl final volume  
Incubate at 37 °C for 1 hour. If the digestion is complete (see 3.1.1. step 1), gel-purify 
the large (7642 bp) fragment and determine DNA concentration (see Note 5).  
2. PCR-amplification of the effector domain (see Note 6). The forward primer 
should contain the 5’-extension AGGCGCGCC consisting of the AscI recognition site 
(underlined) and an A preceding the AscI site. The function of the 5’-A is to ensure 
efficient cleavage of the AscI site located at the end of the PCR product. The last three 
nucleotides of the AscI site (GCC) coincide with a codon (Ala) in the reading frame 
of the dCas9-NLS-3xFLAG-linker peptide fusion protein, thus the first codon of the 
effector protein can be placed directly after the AscI site. The reverse primer should 
contain the 5’-extension GTTAATTAA consisting of the PacI recognition site 
(underlined) and an extra G at the 5’-end. The function of the 5’-G is to ensure 
efficient cleavage of the PacI site located at the end of the PCR product. The reverse 
primer should be designed to contain the complement of an in-frame stop codon. 
Alternatively, one of the two UAA stop codons offered by the PacI site in different 
reading frames can be used to terminate translation at the end of the effector domain 
(see Note 7). The Pfu PCR reaction mixture (25 µl) contains: 
• < 250 ng template DNA 
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• 1 µl forward primer (20 µM) 
• 1 µl reverse primer (20 µM) 
• 0.5 µl dNTP (10 µM) 
• 10X Pfu buffer with 2.5 µl MgSO4 
• 1 µl Pfu DNA polymerase 
• H2O to 25 µl final volume 
After establishing the optimal melting temperature to allow the primers to anneal 
efficiently and specifically, the PCR can be run in a thermocycler. After the PCR 
reaction, check the size of the amplified fragment by running a 3 µl sample of the 
reaction in a 1% agarose gel. If the reaction produced a DNA fragment of the correct 
size, purify the PCR product using a PCR purification kit and measure the 
concentration of the eluted DNA.  
3. Digestion of the PCR product with AscI and PacI: 
• 2 to 4 µg PCR product.  
• 10 µl 10X FastDigest Green Buffer 
• 2 µl FastDigest AscI 
• 2 µl FastDigest PacI 
• H2O to 100 µl final volume 
Incubate at 37 °C for 2 hours. 
Inactivate the restriction enzymes by placing the tubes to 80 °C for 20 min. 
4. Cloning the AscI- and PacI-digested PCR product in pdCas9-NED: 
• ~200 ng AscI- and PacI-digested pdCas9-NED plasmid 
• 200-500 ng AscI- and PacI-digested PCR product  
• 2 µl 10x T4 DNA ligase buffer 
• 1 µl T4 DNA ligase 
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• H2O to 20 µl final volume 
Incubate for 30 minutes - 2 hours at room temperature or at 10 – 15 °C overnight (see 
3.1.1. step 4). Introduce the ligated DNA into E. coli cells by transformation (see 3.1.1. 
step 5).  
5. Isolate plasmid DNA from individual clones using a plasmid miniprep DNA 
isolation kit and analyze the structure of the plasmids by restriction digestion. Pick 2 
– 3 plasmids, which appear to have the correct structure and determine the nucleotide 
sequence of the inserted effector gene. Use sequencing primer 1 and/or 2 (see 2.1 step 
7 A & B). 
 
3.2 Cloning the single guide RNA specifying the addressed genomic sequence 
Plasmid MLM3636 contains a sgRNA expression cassette designed to express custom-made 
sgRNA from a U6 promoter. To obtain a plasmid for guiding the dCas9-effector of interest to 
a specific genomic site, an oligonucleotide containing the 20 bp target sequence is cloned 
between the two BsmBI sites of MLM3636 (Figure 2).  
 
1. Determine the target region to which the dCas9-effector fusion protein should 
bind. Paste the sequence of the wider target region (for example the DNA sequence 
spanning the – 300 bp to + 150 bp segment surrounding the transcription start side) 
into an sgRNA design program (e.g. http://crispr.mit.edu/), and pick the best scoring 
~20 bp guide sequences. 
2. Design the oligonucleotides to be cloned in MLM3636 using the online tool 
“CRISPR/Cas: Design oligos for making guide RNAs” at 
http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx. The program will generate a pair of 
complementary oligonucleotides containing the 20 bp guide (spacer) sequence with 
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added flanking 5’-C and a 3’-G. The duplex formed by the two oligonucleotides will 
carry single-stranded overhangs (5’-ACAC and 5’-AAAA) that are complementary to 
the single-stranded ends generated by BsmBI digestion of MLM3636 (Figure 2). 
Because efficient transcription from the U6 promoter requires a G as starting base, 
select target sites, which start with a G in the top strand. The top strand oligonucleotide 
will have the sequence 5’-ACACCGN19G (Figure 2). Order synthesis of the 
oligonucleotides. 
3. Dissolve the oligonucleotides to 100 µM in TE buffer. Combine: 
• 5μl Oligo 1 
• 5 µl Oligo 2  
• 1  µl 1 M Tris-HCl pH7.5 
• 2  µl 1 M NaCl 
• 7 µl H2O  
Anneal the oligonucleotides (see 3.1.1. step 2). 
4. Digest MLM3636 plasmid DNA with BsmBI in 100 µl digestion mixture: 
• 2 to 4 µg MLM3636 plasmid DNA 
• 10 µl 10X NEBuffer 3.1 
• 2 µl BsmBI 
• H2O to 100 µl final volume 
Incubate at 55 °C for 1 hour. 
5. Check the completeness of the digestion (see 3.1.1. step 1). If the digestion is 
complete, purify the linear DNA fragment from a preparative agarose gel (see 3.1.1. 
step 3). Alternatively, heat-inactivate BsmBI (80 °C, 20 min), and use the digested 
vector directly for ligation. 
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6. Ligate the annealed spacer duplex (Oligo top strand + Oligo bottom strand) into 
the BsmBI-digested MLM3636 plasmid: 
• ~200 ng BsmBI-digested MLM3636 
• Annealed oligo top strand  + oligo bottom strand (2 to 10-fold molar excess over 
the vector) 
• 2µl 10xT4 DNA ligase buffer  
• 1 µl T4 DNA ligase 
• H2O to 20 µl final volume  
Incubate for 30 minutes - 2 hours at room temperature or at 10 – 15 °C overnight (see 
3.1.1. step 4). 
6. Introduce the ligated DNA into E. coli cells by transformation, select ampicillin-
resistant clones (see 3.1.1. step 5). 
7. Isolate plasmid DNA from individual clones using a miniprep DNA isolation 
kit and verify the nucleotide sequence of the inserted guide RNA gene in psgRNA# 
(Figure 2). Use sequencing primer 3 (see 2.1. step 7 C). 
8. Validate the effect of targeted epigenetic editing in transient transfection 
experiments, using appropriate read-outs (Figure 3). 
 
3.3 Construction of plasmids for stable expression of dCas9-effector fusions 
3.3.1 Construction of the vector plasmid pHAGE EF1α dCas9-NED 
The lentiviral expression plasmid vector pHAGE EF1α dCas9-VP64 encodes the fusion protein 
dCas9-VP64 (Figure 4). Transcription of the fusion gene starts from the EF1α promoter. To 
generate an acceptor plasmid for making dCas9-effector fusions, the VP64 gene is deleted from 
pHAGE EF1α dCas9-VP64, and replaced with an oligonucleotide containing a MluI 
(A/CGCGT) and an AsiSI (GCGAT/CGC) site. The new plasmid (pHAGE EF1α dCas9-NED) 
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(Figure 4) will serve as a vector backbone for cloning effector genes. The effector gene, which 
has been tested in the transient expression system, is excised from the pdCas9-effector plasmid 
(see above) by AscI – PacI double-digestion, and transferred into pHAGE EF1α dCas9-NED 
digested with MluI and AsiSI. Because the single-stranded ends generated by AscI are 
compatible with MluI ends, and PacI ends are compatible with AsiSI ends, the effector 
fragment can be transferred directly, in the correct orientation, into pHAGE EF1α dCas9-NED 
to yield pHAGE EF1α dCas9-ED (Figure 4). The dCas9 and the effector gene will be fused in 
the correct reading frame. 
 
1. Digestion of pHAGE EF1α dCas9-VP64 with BamHI and NotI. Prepare the 
reaction mixture: 
• 2 to 4 µg  pHAGE EF1α dCas9-VP64 plasmid  
• 10 µl 10X FastDigest Green buffer 
• 2 µl FastDigest BamHI 
• 2 µl FastDigest NotI 
• H2O to 100 µl 
Incubate at 37 °C for 1 hour. Check the completeness of the digestion (see 3.1.1 step 
1). If the digestion is complete, purify the large, 12534 bp DNA fragment from a 
preparative agarose gel (see 3.1.1. step 3). Measure the concentration of the purified 
DNA fragment (see Note 8). 
2. Annealing of Oligo 3 and Oligo 4. The duplex will contain an MluI and an AsiSI 
site and will carry BamHI- and NotI-compatible single-stranded ends. 
Dissolve the oligonucleotides to 100 µM in TE buffer. Combine: 
• 5μl Oligo 3 
• 5 µl Oligo 4  
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• 1  µl 1 M Tris-HCl pH7.5 
• 2  µl 1 M NaCl 
• 7 µl H2O  
Anneal the oligonucleotides (see 3.1.1. step 2). 
3. Ligation of the annealed oligonucleotides to the purified vector fragment. Prepare 
the following reaction mixture: 
• ~200 ng of the 12 kb fragment of BamHI- and NotI-digested pHAGE EF1α 
dCas9-VP64 
• Annealed Oligos 3+4 (2 to 10-fold molar excess over the vector) 
• 2 µl 10x T4 DNA ligase buffer  
• 1 µl T4 DNA ligase 
• H2O to 20 µl final volume  
Mix gently and incubate for 30 minutes - 2 hours at room temperature or at 10 – 15 °C 
overnight (see 3.1.1. step 4). 
4. Analysis of the clones:  
Transform E. coli with the ligated DNA. Prepare plasmid DNA from ampicillin-
resistant transformants (see 3.1.1. step 5). 
The sought-after plasmid pHAGE EF1α dCas9-NED will contain closely located 
MluI and AsiSI sites. Verify the presence of the inserted oligonucleotide by 
restriction enzyme analysis using these enzymes individually and/or sequence 
across the BamHI and NotI sites. Use sequencing primer 4 (see 2.1 step 7 D). 
 
3.3.2 Construction of the plasmids for stable expression of dCas9-effector fusions  
1. Isolation of the effector gene from the pdCas9-effector plasmid. Prepare the 
following reaction mixture: 
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• 2 to 4 µg  pdCas9-effector plasmid 
• 10 µl 10X FastDigest Green buffer 
• 2 µl FastDigest AscI 
• 2 µl FastDigest PacI 
• H2O to 100 µl 
Incubate at 37 °C for 1 hour. Check the completeness of the digestion. If the digestion 
is complete, purify the DNA fragment encoding the effector domain from a 
preparative agarose gel (see 3.1.1 step 3). Measure the concentration of the purified 
DNA fragment. 
2. Isolation of the pHAGE EF1α dCas9-NED backbone.  Prepare the following 
reaction mixture: 
• 2 to 4 µg  pHAGE EF1α dCas9-NED plasmid 
• 10 µl 10X FastDigest Green buffer 
• 2 µl FastDigest MluI 
• 2 µl FastDigest AsiSI 
• H2O to 100 µl 
Incubate at 37 °C for 1 hour. Check the completeness of the digestion. If the digestion 
is complete, purify the linear vector fragment from a preparative agarose gel (see 
3.1.1. step 3). Measure the concentration of the purified DNA fragment. 
3. Cloning of the effector gene in pHAGE EF1α-dCas9-NED. Prepare the following 
reaction mixture: 
• ~200 ng MluI- and AsiSI-digested pHAGE EF1α dCas9-NED 
• ~200 ng AscI- and PacI-digested effector fragment 
• 2 µl 10x T4 DNA ligase buffer  
• 1 µl T4 DNA ligase 
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• H2O to 20 µl final volume  
Mix gently and incubate for 30 minutes - 2 hours at room temperature or at 10 – 15 °C 
overnight (see 3.1.1. step 4). 
4. Analysis of the clones:  
Transform E. coli with the ligated DNA. Prepare plasmid DNA from ampicillin-
resistant transformants (see 3.1.1. step 5). Analyze the structure of the plasmids by 
restriction digestions. 
 
3.4 Establishing kinetics of epigenetic editing 
3.4.1 Construction of stable dCas9-effector expressing cell lines (Figure 5) 
1. Day 0: Seed the HEK293T cells at a density of 4 x 106 cells per 10 cm plate (1 
per construct) in 10 ml medium (see Notes 9 and 10). 
2. Day 1: TRANSFECTION (see Note 11) - prepare in a tube the following 
transfection mixture (per plate/construct): 
• 3.75 ml DMEM serum free  
• 2 µg psPAX2  
• 5 µg pMD2.G-VSV-G  
• 5 µg pHAGE EF1α dCas9-ED 
• 12 µl PLUS reagent 
Mix the content of the tube and incubate at RT for 3-5 minutes. 
3. Add 22 µl LTX reagent to the same tube, mix and incubate 20 min at RT. 
4. In the meantime, add fresh pre-warmed medium (10 ml) to HEK293T cells 
plated on day 0 (see Note 12). 
5. After the incubation, pipet the transfection mix carefully (drop by drop) on the 
medium of the HEK293T cells. 
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6. Carefully swirl the plate, so that the transfection mix is properly divided. 
7. Incubate the plates for 24 hours at 37 °C, in a 5% CO2 containing humidified 
incubator 
8. Day 2: (T=24h after transfection) (see Note 13) replace the medium of the 
transfected HEK293T cells with 7 ml fresh medium and incubate for another 24 
hours (see Notes 14-16). 
9. Seed your host cells. The density and size of the culture flask/wells depends on 
the type of experiment you want to perform (see Notes 17 and 18). 
10. Day 3: (T=48h after transfection) Transfer the medium of the transfected 
HEK293T plate (= Virus supernatant) into a 10 ml syringe and filter it through 
a SFCA 0.40 μ filter into a 15 ml tube, to get rid of the HEK293T cells (see 
Note 19), and clean the filter and the syringe by rinsing with disinfectant. 
11. Add 7 ml fresh medium to the HEK293T cells. Harvest virus-containing 
supernatant again at day 4 in the afternoon.  
12. TRANSDUCTION of host cells: thaw frozen virus supernatant at 37 ˚C for 20 
min or use fresh virus supernatant. As a guideline, use 1.5 ml for 6 wells, 3.5 
ml for T25 and 8 ml for T75 culture flasks. Per ml virus supernatant add: 100 
µl FBS and 8µg/ml Polybrene Mix to host cells, do NOT add any other medium. 
13. Day 4: repeat step 10. Store the virus-containing supernatant at -20˚C or add 
again to the host cells (step 12) (see Note 20). 
14. Add disinfectant solution to the HEK293T plates, let it stand for 15 minutes, 
aspirate and discard appropriately. 
15. After 6-8 hours of the second transduction step of the host cells: aspirate the 
media of host cells and put them on normal medium. 
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16. Day 7: Aspirate the medium from the host cells and add selection medium 
(DMEM + 8 µg/ml puromycin) for 4 days (cells should be passaged when 
confluent).  
17. Subsequently the resulting stable cell lines should be cultured in 1 µg/ml 
puromycin-supplemented medium and can be stored in liquid N2 
18. Upon thawing and subculturing, select for stable expressing cells using 1 µg/ml 
puromycin-supplemented medium after they have been in culture for 1 week. 
 
3.4.2 Transfection of stable cell lines (see Note 21). 
The above constructed stable cells will constantly express the dCas9-effector fusions. By 
transiently transfecting these cells with psgRNA# of interest (Figure 5) (see 3.2.), the long 
term kinetics of expression modulation can be assessed because the expression of sgRNAs 
will fade out. 
1. Day 0: Seed the desired stable cell line with approximately 500,000 cells per 
well in a six-well plate in 1 µg/ml puromycin-supplemented medium. 
2. Day 1: Using the desired transfection agent, transfect up to 2µg of the 
pMLM3636-derived plasmid(s) expressing the sgRNA(s) designed to target 
your gene of interest. 
3. Day 3: Collect cells, and quantify RNA expression using standard assays to 
determine the initial/short-term effects. 
4. Day 12: Collect cells after a desired number of days (f.e. 12 days) and analyze 
the long-term kinetics of the epigenetic marks and gene expression using the 









1. Cell lines should always be tested for mycoplasma contamination and can be 
authenticated using short tandem repeats (STR) profiling. 
2. The lab in which viral particles are being handled should at least be of biosafety level 
2, allowing work to be carried out with potential pathogenic or infectious organisms 
posing a moderate hazard. The lab should be equipped with special safety equipment 
and physical barriers like safety cabinets and biohazard warning signs at all access 
points. Immunocompromised or immunosuppressed people might be denied access to 
the lab and immunizations to f.e. hepatitis B might be required. Adhere to local rules 
regarding application, declaration, and documentation of experiments. 
3. Alternatively, the ligation mixture can be incubated at lower temperature (10 – 15 °C) 
overnight. Prolonged incubation can increase the efficiency of ligation. 
4. Because of the close location of the AscI and the AgeI sites, complete digestion of the 
plasmid is difficult to obtain. Incomplete digestion of one or both sites can result in a 
large number of empty vectors without inserted oligonucleotide. To estimate the 
background resulting from such partially digested molecules, setting-up of a “self-
ligation” reaction (without the annealed oligos) is recommended. 
5. Due to different conditions required by the two enzymes, complete digestion can be 
difficult to achieve with conventional restriction enzyme preparations. For conventional 
restriction enzymes, performing the digestion in two steps in optimal buffers with DNA 
purification in between is recommended, although dilution to change the buffer might 
work as well. 
6. As a control, catalytically inactive mutant effector domains should be used, which can 
be obtained through site-directed mutagenesis of the wild-type effector. 
7. Make sure that the coding sequence of the effector does not contain AscI or PacI site 
(AscI and PacI recognize 8 bp sites thus cut very rarely). 
8. pHAGE EF1α dCas9-VP64 contains two closely located NotI sites. BamHI – NotI 
double digestion deletes the 64 bp NotI-NotI fragment. 
9. Do not let the cells grow to full confluency, 70 % is perfect. 
10. Preferably seed in the afternoon of day 0, this ensures a better time-schedule for the rest 
of the procedure. 
11. Preferably in the afternoon (24 h after seeding at a confluency of 70%). 
12. HEK293T cells detach very easily. Let the medium slide over the walls of the plate 




The more medium added, the less concentrated the virus will be. For direct application 
to cells this will not be a huge problem, but when freezing the virus supernatant, this 
could affect infection efficiency. Every freeze-thaw cycle approximately halves the 
amount of viable virus particles. 
13. Should be performed in the afternoon to ensure an optimal time schedule for the rest of 
the procedure. 
14. Be careful not to get contact with bare skin 
15. Clean the surfaces and all equipment thoroughly with ethanol. 
16. Dispose of virus-containing medium and virus-contaminated pipets by placing these 
straight into disinfectant in order to inactivate the virus. 
17. Should be performed in the afternoon ensure an optimal time schedule for the rest of 
the procedure. 
18. As a guidance: seed 9,000 cells/cm2 for 3-4 days of recovery after addition of virus. 
19. Use directly for infection or store at -20˚C; make sure to label properly: “DANGER 
active virus” etc. 
20. Perform this step early in the morning, so step 15 can be performed in the afternoon. 
21. Efficiency of transfection and expression decreases with increasing plasmid size. If 
possible, do not use plasmids larger than 14 kb. 
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Legends to Figures 
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Figure 1. Construction of plasmids expressing dCas9-effector fusion proteins. The 
plasmid pMLM3705 encoding a dCas9-VP64 fusion is converted into a general 
acceptor plasmid pdCas9-NED by digestion with AscI and AgeI. The new plasmid will 
encode the fusion protein dCas9-SV40 nuclear localization signal (NLS) - 3xFLAG 
peptide, and will serve as an acceptor for genes of effector domains which can be 
inserted between the AscI and the PacI sites. 
 
Figure 2. Construction of plasmids expressing single-guide RNA. The double-stranded 
oligonucleotide specifying the target sequence (20 bp) is cloned between the BsmBI 
sites of MLM3636 (bold in psgRNS#). 
Figure 3. Workflow of transient transfection experiments designed to study the effect 
of targeting dCas9-linked epigenetic effectors to a genomic site. The plasmids 
expressing the specific sgRNAs to target the gene of interest (psgRNA) and the pdCas9-
ED are transfected in the target cells. After 48 hours, cells are collected and RNA/DNA 
can be isolated to validate the effect of targeted epigenetic editing , using the 
appropriate read-outs. 
 
Figure 4. Construction of lentiviral vector plasmids expressing dCas9-effector fusion 
proteins. The plasmid pHAGE EF1α dCas9-VP64 encoding a dCas9-VP64 fusion is 
converted into a general acceptor plasmid pHAGE EF1α dCas9-NED by digestion with 
BamHI and NotI. The new plasmid will containing a MluI (A/CGCGT) and an AsiSI 
(GCGAT/CGC) site, of which the ends are compatible with AscI and PacI ends, so that 
effector fragments can be transferred directly, in the correct orientation, to yield 




Figure 5. Experimental system designed to study the effect of targeting dCas9-linked 
epigenetic effector to a specific genomic locus in mammalian cell lines permanently 
expressing the dCas9-effector fusion protein. The plasmid expressing the sgRNA, 
which determines target specificity, is introduced by transient transfection. 
 
 
